Genentech has broken ground on a $750m expansion in Hillsboro, Oregon, doubling the site to add device fill-finish capacity and about 250 jobs.
The Roche subsidiary’s 211,000 sq ft expansion will focus on filling drug-delivery devices, including combination products, for oncology, neurology and immunology treatments.
The expansion at a glance
- Investment: $750m
- Location: Hillsboro, Oregon
- Size: 211,000 sq ft, doubling the site
- Purpose: Device fill-finish, including combination products
- Therapy areas: Oncology, neurology and immunology
- Jobs: About 250 manufacturing roles
- Timeline: Commercial operations planned for 2031
What the jobs involve
The new roles span filling and inspection, device assembly and packaging, cold storage and quality control. These are the final steps between making a drug and getting it to patients.
Why device fill-finish matters
More medicines are now delivered in autoinjectors and prefilled devices, often so patients can treat themselves at home. That puts pressure on fill-finish capacity, one of the industry’s recurring bottlenecks. By building its own capacity, Genentech reduces its reliance on outside contract manufacturers for this step.
Why it matters
- US onshoring continues. The expansion adds to a wave of US manufacturing investment by large drugmakers.
- The device shift. Combination products and self-administration are growing, and capacity needs to follow.
- Long horizon. As with other recent announcements, production will not start until 2031.
What it means for suppliers
A fill-finish expansion of this scale needs components and services: device parts, syringes, cartridges, packaging, inspection equipment and cold storage. Suppliers to the Pacific Northwest life sciences cluster should take note.
The bottom line
Genentech’s $750m Hillsboro expansion targets one of the tightest parts of the pharmaceutical supply chain. It is another long-term investment in US capacity for complex medicines.
Frequently Asked Questions
How much is Genentech investing in Hillsboro? $750m to expand its manufacturing site in Hillsboro, Oregon.
What will the expansion do? Add device fill-finish capacity, including combination products, for oncology, neurology and immunology drugs.
How many jobs will it create? About 250 manufacturing jobs.
When will it be operational? Commercial operations are planned for 2031.
Sources
| Source | Used for |
|---|---|
| Contract Pharma | Investment, site size, roles and timeline |
| Business Wire (Genentech announcement) | Groundbreaking announcement |
| Pharma Manufacturing | Expansion coverage |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Roche investor relations | Group manufacturing strategy |
| Oregon Business Development Department (Business Oregon) | State economic development and life sciences projects |
| International Society for Pharmaceutical Engineering (ISPE) | Fill-finish and facility design guidance |
| US Food and Drug Administration (FDA) | Combination product regulation |
Data note: The specific medicines to be filled at the site were not confirmed in available reporting.